Our Focus

We are focused on developing and delivering innovative therapies that provide hope and healing for patients living with cancer. The company is conducting a pivotal clinical trial of its lead drug candidate, galeterone, in patients with metastatic castration resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor that has been associated with non-responsiveness to commonly-used oral therapies for mCRPC. This trial is the first precision medicine-based pivotal clinical trial in prostate cancer, and top-line data from the study are expected by mid-2017.

Read More


Tokai’s lead product candidate is galeterone, a highly-selective, oral small molecule with the potential to transform the treatment of prostate cancer.


We are focusing our late-stage development of galeterone on the treatment of men with metastatic, castration-resistant prostate cancer, whose prostate tumor cells express the AR-V7 splice variant. We are collaborating with Qiagen to develop and commercialize an AR-V7 companion diagnostic test for use with galeterone.

androgen receptor degradation

Galeterone’s activity in AR-V7 positive CRPC patients is attributable to its activity as an androgen receptor degrader. We also have a platform to identify and develop novel, next-generation compounds that have potent androgen receptor degradation activity.

Clinical Trials

ARMOR (Androgen Receptor Modulation Optimized for Response) is Tokai’s clinical development program for the evaluation of galeterone in patients with prostate cancer.

Learn More